National survey of extended-interval aminoglycoside dosing

被引:69
|
作者
Chuck, SK
Raber, SR
Rodvold, KA
Areff, D
机构
[1] Univ Illinois, Coll Pharm, Dept Pharm Practice, Chicago, IL 60612 USA
[2] Univ Illinois, Coll Med, Infect Dis Sect, Chicago, IL 60612 USA
[3] Oregon State Univ, Coll Pharm, Portland, OR USA
[4] Providence Med Ctr, Dept Pharm, Portland, OR USA
[5] Providence Med Ctr, Dept Med Educ, Portland, OR USA
关键词
D O I
10.1086/313692
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A random sample survey of 500 acute care hospitals in the United States was conducted to evaluate the adoption of extended-interval aminoglycoside dosing (EIAD). The survey revealed that EIAD has been adopted in 3 of every 4 acute care hospitals, a 4-fold increase since 1993. Of the 74.7% of hospitals reporting EIAD, 64% had written guidelines. Equal or less toxicity (87.1%), equal efficacy (76.9%), and cost-savings (65.6%) were common rationales. There has been a trend toward higher adult dosages of gentamicin (e.g., >5 mg/kg/dose) and an increase in the adoption of EIAD across all age groups (neonatal, 11%, and pediatric, 23%). Monitoring of aminoglycoside concentrations has shifted to a single determination of concentration, at 6-18 h after drug administration. The most common methods of dosage adjustment for declining renal function were an interval extension with the same dose (47%) or use of the Hartford nomogram (32%).
引用
收藏
页码:433 / 439
页数:7
相关论文
共 50 条
  • [1] Extended-interval Aminoglycoside Dosing in Pediatrics
    Jenh, Alice M.
    Tamma, Pranita D.
    Milstone, Aaron M.
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2011, 30 (04) : 338 - 339
  • [2] Intrapatient variability of aminoglycoside pharmacokinetic parameters in simulated extended-interval aminoglycoside dosing
    Chapman, SA
    Wacksman, GP
    [J]. CRITICAL CARE MEDICINE, 1999, 27 (12) : A93 - A93
  • [3] Extended-interval aminoglycoside dosing for treatment of enterococcal and staphylococcal osteomyelitis
    Graham, AC
    Mercier, RC
    Achusim, LE
    Pai, MP
    [J]. ANNALS OF PHARMACOTHERAPY, 2004, 38 (06) : 936 - 941
  • [4] A Survey of Extended-Interval Aminoglycoside Dosing Practices in United States Adult Cystic Fibrosis Programs
    Prescott, William A., Jr.
    [J]. RESPIRATORY CARE, 2014, 59 (09) : 1353 - 1359
  • [5] Extended-interval dosing of aminoglycosides
    Blam, ME
    Hammer, GS
    [J]. MOUNT SINAI JOURNAL OF MEDICINE, 1997, 64 (06): : 386 - 391
  • [6] Extended-interval dosing of natalizumab in NOVA
    Stuve, Olaf
    Tugemann, Bastian
    [J]. LANCET NEUROLOGY, 2023, 22 (03): : 199 - 200
  • [7] Extended-Interval Gentamicin Dosing for Pulmonic Tularemia
    Dietrich, Tyson
    Garcia, Katelynn
    Strain, Joe
    Ashurst, John
    [J]. CASE REPORTS IN INFECTIOUS DISEASES, 2019, 2019
  • [8] Extended-interval dosing of natalizumab in NOVA Reply
    Foley, John F.
    Campbell, Nolan
    Kong, George
    [J]. LANCET NEUROLOGY, 2023, 22 (03): : 200 - 201
  • [9] Extended-Interval Dosing of Aminoglycosides in Pediatrics: A Narrative Review
    Salehifar, Ebrahim
    Rafati, Mohammad Reza
    [J]. JOURNAL OF PEDIATRICS REVIEW, 2015, 3 (02)
  • [10] Extended-interval aminoglycoside administration for children: A meta-analysis
    Contopoulos-Ioannidis, DG
    Giotis, ND
    Baliatsa, DV
    Ioannidis, JPA
    [J]. PEDIATRICS, 2004, 114 (01) : E111 - E118